305 related articles for article (PubMed ID: 38366287)
21. Comparison of 3 Paclitaxel-Based Chemoradiotherapy Regimens for Patients With Locally Advanced Esophageal Squamous Cell Cancer: A Randomized Clinical Trial.
Ai D; Ye J; Wei S; Li Y; Luo H; Cao J; Zhu Z; Zhao W; Lin Q; Yang H; Zheng X; Zhou J; Huang G; Li L; Li J; Zhang Z; Zhou G; Gu D; Du M; Mo M; Jia H; Zhang Z; Zhao K
JAMA Netw Open; 2022 Feb; 5(2):e220120. PubMed ID: 35188552
[TBL] [Abstract][Full Text] [Related]
22. Sintilimab as maintenance treatment for local/regional recurrent esophageal squamous carcinoma after concurrent chemoradiotherapy: a single-arm Ib/II phase study.
Liu C; Sun H; Huang W; Wang Z; Fu C; Han D; Zhao Q; Wu X; Li B
Front Immunol; 2023; 14():1193394. PubMed ID: 37325650
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the clinical efficacy between single-agent and dual-agent concurrent chemoradiotherapy in the treatment of unresectable esophageal squamous cell carcinoma: a multicenter retrospective analysis.
Li J; Gong Y; Diao P; Huang Q; Wen Y; Lin B; Cai H; Tian H; He B; Ji L; Guo P; Miao J; Du X
Radiat Oncol; 2018 Jan; 13(1):12. PubMed ID: 29357883
[TBL] [Abstract][Full Text] [Related]
24. Comparative study of cisplatin-based definitive concurrent chemoradiotherapy with S-1 versus paclitaxel for unresectable locally advanced esophageal squamous cell carcinoma.
Fang M; Song T; Liang X; Lv S; Li J; Xu H; Luo L; Jia Y
Oncotarget; 2017 Jun; 8(23):37080-37090. PubMed ID: 28415745
[TBL] [Abstract][Full Text] [Related]
25. Induction versus adjuvant chemotherapy combined with concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
Mu X; Liu H; Wu J; Chen S; Peng X; Wang J; Wei Z; He L; Liu J; Lu Z; Su Y
Aging (Albany NY); 2022 Aug; 14(16):6727-6739. PubMed ID: 36036759
[TBL] [Abstract][Full Text] [Related]
26. Neck Lymph Node Metastasis as A Poor Prognostic Factor in Thoracic Esophageal Squamous Cell Carcinoma Patients Receiving Concurrent Chemoradiotherapy: A Propensity Score-Matched Analysis.
Chen YH; Lu HI; Lo CM; Wang YM; Chou SY; Hsiao CC; Shih LH; Chen SW; Li SH
Sci Rep; 2018 Oct; 8(1):15073. PubMed ID: 30305678
[TBL] [Abstract][Full Text] [Related]
27. Adjuvant chemotherapy after concurrent chemoradiation for locally advanced cervical cancer.
Tangjitgamol S; Katanyoo K; Laopaiboon M; Lumbiganon P; Manusirivithaya S; Supawattanabodee B
Cochrane Database Syst Rev; 2014 Dec; 2014(12):CD010401. PubMed ID: 25470408
[TBL] [Abstract][Full Text] [Related]
28. Treatment Outcomes of Patients with Locally Advanced Synchronous Esophageal and Head/Neck Squamous Cell Carcinoma Receiving Curative Concurrent Chemoradiotherapy.
Chen YH; Lu HI; Chien CY; Lo CM; Wang YM; Chou SY; Su YY; Shih LH; Li SH
Sci Rep; 2017 Jan; 7():41785. PubMed ID: 28134308
[TBL] [Abstract][Full Text] [Related]
29. The efficacy and safety of docetaxel, cisplatin and fluorouracil (TPF)-based induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis.
Zhou R; Zhu J; Chen X; Liu Y; Wang Y; Zhang T
Clin Transl Oncol; 2020 Mar; 22(3):429-439. PubMed ID: 31165410
[TBL] [Abstract][Full Text] [Related]
30. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
Wei Z; Zhang Z; Luo J; Li N; Peng X
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162
[TBL] [Abstract][Full Text] [Related]
31. Prognostic value of Hematoxylin and eosin staining tumor-infiltrating lymphocytes (H&E-TILs) in patients with esophageal squamous cell carcinoma treated with chemoradiotherapy.
Zheng J; Zhang H; Li S; Kang Z; Zheng F; Yao Q; Zhang X; Wu Z; Wang J; Fang W; Li J; Chen G; Chen Y; Chen M
BMC Cancer; 2023 Dec; 23(1):1193. PubMed ID: 38053017
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the Clinical Outcomes of Esophagectomy and Concurrent Chemoradiotherapy in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma.
Lee MH; Park MI; Lee JW; Jung K; Kim JH; Kim SE; Moon W; Park SJ
Korean J Gastroenterol; 2024 Mar; 83(3):102-110. PubMed ID: 38522853
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant vs definitive concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma patients.
Chen CY; Li CC; Chien CR
World J Surg Oncol; 2018 Jul; 16(1):141. PubMed ID: 30007409
[TBL] [Abstract][Full Text] [Related]
34. Improved prognosis with induction chemotherapy in pathological complete responders after trimodality treatment for esophageal squamous cell carcinoma: Hypothesis generating for adjuvant treatment.
Lu SL; Hsu FM; Tsai CL; Lee JM; Huang PM; Hsu CH; Lin CC; Chang YL; Hsieh MS; Cheng JC
Eur J Surg Oncol; 2019 Aug; 45(8):1498-1504. PubMed ID: 30910457
[TBL] [Abstract][Full Text] [Related]
35. Positron-Emission Tomography Scan-Directed Chemoradiation for Esophageal Squamous Cell Carcinoma: No Benefit for a Change in Chemotherapy in Positron-Emission Tomography Nonresponders.
Greally M; Chou JF; Molena D; Rusch VW; Bains MS; Park BJ; Wu AJ; Goodman KA; Kelsen DP; Janjigian YY; Ilson DH; Ku GY
J Thorac Oncol; 2019 Mar; 14(3):540-546. PubMed ID: 30391577
[TBL] [Abstract][Full Text] [Related]
36. The Benefits of Docetaxel Plus Cisplatin and 5-Fluorouracil Induction Therapy in Conversion to Curative Treatment for Locally Advanced Esophageal Squamous Cell Carcinoma.
Takeuchi M; Kawakubo H; Mayanagi S; Yoshida K; Irino T; Fukuda K; Nakamura R; Wada N; Takeuchi H; Kitagawa Y
World J Surg; 2019 Aug; 43(8):2006-2015. PubMed ID: 30972432
[TBL] [Abstract][Full Text] [Related]
37. Survival outcomes of neoadjuvant immunochemotherapy versus chemotherapy for locally advanced esophageal squamous cell carcinoma.
Lv H; Zhang F; Huang C; Xu S; Li J; Sun B; Gai C; Liu Z; Wang M; Li Z; Tian Z
J Cancer Res Clin Oncol; 2024 May; 150(5):260. PubMed ID: 38760614
[TBL] [Abstract][Full Text] [Related]
38. A retrospective study comparing definitive chemoradiotherapy vs. chemoradiotherapy followed by surgery in T4 esophageal squamous cell carcinoma patients who were downstaged after neochemoradiotherapy.
Zhang T; Guo Z; Chen X; Dong J; Jiang H; Tang P; Wang P; Qian D; Zhang W; Pang Q
Radiat Oncol; 2022 Aug; 17(1):148. PubMed ID: 35999608
[TBL] [Abstract][Full Text] [Related]
39. Immune checkpoint inhibitors combined with concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma.
Huang JQ; Liang HW; Liu Y; Chen L; Pei S; Yu BB; Pan XB
Front Immunol; 2024; 15():1355198. PubMed ID: 38550598
[TBL] [Abstract][Full Text] [Related]
40. Clinical outcomes and toxicities of locally advanced esophageal squamous cell carcinoma patients treated with early thoracic radiation therapy after induction chemotherapy.
Qiu J; Lin H; Yu Y; Ke D; Li H; Zheng H; Zheng Q; Wang Z; Lin M; Yang J; Liu L; Zhang M; Liu T; Wu Y; Li J; Lai J
Int J Clin Oncol; 2023 Apr; 28(4):550-564. PubMed ID: 36735115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
